


Calculate the quantity, in mg, of  $C_{9}H_{11}FN_2O_5$  in the portion of Floxuridine for Injection taken by the formula:

$$5C(A_U / A_S)$$

in which  $C$  is the concentration, in  $\mu\text{g}$  per mL, of USP Floxuridine RS in the Standard solution; and  $A_U$  and  $A_S$  are the absorbances of the solution from Floxuridine for Injection and the Standard solution, respectively.

## Fluconazole



$C_{13}H_{12}F_2N_6O$  306.27  
1*H*-1,2,4-Triazole-1-ethanol, 1-(2,4-difluorophenyl)-1-(1*H*-1,2,4-triazol-1-ylmethyl)-;  
2,4-Difluoro-1',1'-bis(1*H*-1,2,4-triazol-1-ylmethyl)benzyl alcohol [86386-73-4].

### DEFINITION

Fluconazole contains NLT 98.0% and NMT 102.0% of  $C_{13}H_{12}F_2N_6O$ , calculated on the dried basis.

### IDENTIFICATION

- A. INFRARED ABSORPTION** (197K)
- B. ULTRAVIOLET ABSORPTION** (197U)

Sample solution: 200  $\mu\text{g/mL}$

Medium: Alcohol

### ASSAY

#### PROCEDURE

**Sample solution:** Dissolve 200 mg of Fluconazole in 100 mL of glacial acetic acid.

**Analysis:** Titrate with 0.1 N per chloric acid VS, using a suitable anhydrous electrode system. Per form a blank determination, and make any necessary correction. Each mL of 0.1 N perchloric acid is equivalent to 15.31 mg of fluconazole ( $C_{13}H_{12}F_2N_6O$ ).

**Acceptance criteria:** 98.0%–102.0% on the dried basis

### IMPURITIES

[NOTE—On the basis of information regarding the manufacturing process, perform either: (a) *Organic Impurities, Procedure 1* or (b) *Organic Impurities, Procedure 2* and *Organic Impurities, Procedure 3*.]

#### ORGANIC IMPURITIES, PROCEDURE 1

**Mobile phase:** Acetonitrile and water (20:80)

**Standard solution:** 10  $\mu\text{g/mL}$  each of USP Fluconazole RS, USP Fluconazole Related Compound A RS, USP Fluconazole Related Compound B RS, and USP Fluconazole Related Compound C RS, dissolved in acetonitrile, and then diluted in *Mobile phase*

**Sample solution:** 3 mg/mL of Fluconazole in *Mobile phase*

#### Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

**Mode:** LC

**Detector:** UV 260 nm

**Column:** 4.6-mm  $\times$  15-cm; 3.5- $\mu\text{m}$  packing L1

**Column temperature:** 40°

**Flow rate:** 0.5 mL/min

**Injection size:** 20  $\mu\text{L}$

#### System suitability

**Sample:** *Standard solution*

[NOTE—The retention times for fluconazole related compound A, fluconazole related compound B, fluconazole related compound C, and fluconazole are about 4.9, 8.0, 8.5, and 9.9 min, respectively.]

### Suitability requirements

**Resolution:** NLT 1.5 between fluconazole related compound B and fluconazole related compound C

**Relative standard deviation:** NMT 5.0% for each peak

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of fluconazole related compound A, fluconazole related compound B, and fluconazole related compound C in the portion of Fluconazole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of fluconazole related compound A, fluconazole related compound B, or fluconazole related compound C from the *Sample solution*

$r_S$  = average peak response of fluconazole related compound A, fluconazole related compound B, and fluconazole related compound C for replicate injections of the *Standard solution*

$C_S$  = concentration of USP Fluconazole Related Compound A RS, USP Fluconazole Related Compound B RS, and USP Fluconazole Related Compound C RS in the *Standard solution* (mg/mL)

$C_U$  = concentration of Fluconazole in the *Sample solution* (mg/mL)

Calculate the percentage of any other impurities in the portion of Fluconazole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of any other impurity from the *Sample solution*

$r_S$  = average peak response of fluconazole for replicate injections of the *Standard solution*

$C_S$  = concentration of USP Fluconazole RS in the *Standard solution* (mg/mL)

$C_U$  = concentration of Fluconazole in the *Sample solution* (mg/mL)

**Acceptance criteria:** See *Table 1*.

**Table 1**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Fluconazole related compound A	0.5	0.2
Fluconazole related compound B	0.81	0.1
Fluconazole related compound C	0.86	0.2
Fluconazole	1.0	—
Specified impurity	0.6	1.0
Any other individual impurity	—	0.1
Total unknown impurities	—	0.3
Total impurities	—	1.5

#### ORGANIC IMPURITIES, PROCEDURE 2

**Solution A:** 0.01 M anhydrous sodium acetate solution.

Adjust with 1 N acetic acid to a pH of 5.0, filter, and degas.

**Solution B:** Acetonitrile

**Solution C:** Methanol

**Mobile phase:** See *Table 2*.

**Table 2**

Time (min)	Solution A (%)	Solution B (%)	Solution C (%)
0	80	5	15
10	80	5	15
20	30	55	15
23	30	55	15
25	80	5	15
30	80	5	15

**Diluent:** Methanol and *Solution A* (16:84)

**Standard solution:** 0.01 mg/mL of USP Fluconazole RS in *Diluent*

**System suitability solution:** 0.02 mg/mL of USP Fluconazole RS and 6 µg/mL of USP Desacetyl Diltiazem Hydrochloride RS in *Diluent*

**Sample solution:** 2 mg/mL of Fluconazole in *Diluent*

#### Chromatographic system

(See *Chromatography* <621>, *System Suitability*.)

**Mode:** LC

**Detector:** UV 261 nm

**Column:** 4.0-mm × 10-cm; packing L1

**Flow rate:** 1 mL/min

**Injection size:** 20 µL

#### System suitability

**Samples:** *Standard solution* and *System suitability solution*  
[NOTE—The relative retention times for fluconazole and desacetyl diltiazem are 1.0 and 1.2, respectively, *System suitability solution*.]

#### Suitability requirements

**Resolution:** NLT 10.0 between fluconazole and desacetyl diltiazem hydrochloride, *System suitability solution*

**Column efficiency:** NLT 30,000 theoretical plates for the fluconazole peak, *System suitability solution*

**Tailing factor:** NMT 1.4 for the fluconazole peak, *System suitability solution*

**Relative standard deviation:** NMT 5.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Fluconazole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

$r_U$  = peak response of each impurity from the *Sample solution*

$r_S$  = peak response of fluconazole from the *Standard solution*

$C_S$  = concentration of USP Fluconazole RS in the *Standard solution* (mg/mL)

$C_U$  = concentration of Fluconazole in the *Sample solution* (mg/mL)

$F$  = relative response factor (see *Table 3*)

**Acceptance criteria:** See *Table 3*.

**Table 3**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Specified impurity	0.17–0.37	0.72	0.1
Specified impurity	0.48–0.60	0.85	0.1
Specified impurity	0.67–0.79	1.21	0.1
Specified impurity	1.14–1.18	0.96	0.1
Specified impurity	1.20–1.32	0.97	0.1
Any unspecified impurity	—	1.0	0.1
Total impurities	—	—	0.5

#### • ORGANIC IMPURITIES, PROCEDURE 3

**Standard solution A:** 1 mg/mL of USP Fluconazole RS in methanol (2.0%)

**Standard solution B:** 0.1 mg/mL of USP Fluconazole RS from *Standard solution A* in methanol (0.2%)

**Standard solution C:** 0.05 mg/mL of USP Fluconazole RS from *Standard solution A* in methanol (0.1%)

**Sample solution:** 50 mg/mL of Fluconazole in methanol

#### Chromatographic system

(See *Chromatography* <621>, *Thin-Layer Chromatography*.)

**Mode:** TLC

**Adsorbent:** 0.25-mm layer of chromatographic silica gel mixture

**Application volume:** 10 µL

**Developing solvent system:** Chloroform, methanol, and ammonium hydroxide (80:20:1)

**Spray reagent A:** 1.7 mg/mL of silver nitrate in water

**Spray reagent B (potassium iodoplatinate solution):** 375 mg of chloroplatinic acid in 5 mL of 1 N hydrochloric acid. Dissolve 5 g of potassium iodide in 50 mL of water, and store in a light-resistant container. Prepare a mixture of water, potassium iodide solution, and chloroplatinic acid solution (20:9:1).

#### Analysis

**Samples:** *Standard solution A*, *Standard solution B*, *Standard solution C*, and *Sample solution*

Spray the dry plate with *Spray reagent A*, and expose the plate to 365-nm UV light for 10–20 min. Dry the plate for 20 min between 80° and 90°, then spray the plate with *Spray reagent B*. Allow the plate to dry. Examine the plate and compare the intensities of any secondary spots observed in the *Sample solution* with those of the principal spots in the *Standard solutions*.

**Acceptance criteria:** No spot from the *Sample solution* with an  $R_f$  value between 0.10–0.25 and 0.27–0.41 is larger or more intense than that from *Standard solution B* (0.2%).

• **RESIDUE ON IGNITION (281):** NMT 0.1%

**Sample:** 0.5 g

• **IRON (241)**

**Sample solution:** Transfer 0.5 g of the sample into a test tube. Dissolve in 5 mL of alcohol, and add 5 mL of distilled water.

**Acceptance criteria:** NMT 20 ppm

#### SPECIFIC TESTS

• **LOSS ON DRYING (731):** Dry a sample at 105° for 3 h: it loses NMT 0.5% of its weight.

• **CLARITY AND COLOR OF SOLUTION**

**Sample solution:** Dissolve a sample in methanol to obtain a 5-in-100 solution (w/v).

**Acceptance criteria:** The solution is clear and colorless.

#### ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in tight containers, and store below 30°.

• **LABELING:** If a procedure for *Organic Impurities* other than *Procedure 1* is used, then the labeling states with which *Organic Impurities* procedure(s) the article complies.

• **USP REFERENCE STANDARDS (11)**

USP Desacetyl Diltiazem Hydrochloride RS

$C_{20}H_{24}N_2O_3S \cdot HCl$  408.95

USP Fluconazole RS

USP Fluconazole Related Compound A RS

2-[2-Fluoro-4-(1*H*-1,2,4-triazol-1-yl)phenyl]-1,3-bis(1*H*-1,2,4-triazol-1-yl)-propan-2-ol.

USP Fluconazole Related Compound B RS

2-(4-Fluorophenyl)-1,3-bis(1*H*-1,2,4-triazol-1-yl)-propan-2-ol.

USP Fluconazole Related Compound C RS

1,1'-(1,3-Phenylene)di(1*H*-1,2,4-triazole).

## Fluconazole Injection

#### DEFINITION

Fluconazole Injection is a sterile solution of Fluconazole in a suitable vehicle. It contains NLT 90.0% and NMT 110.0% of the labeled amount of fluconazole ( $C_{13}H_{12}F_2N_6O$ ).

#### IDENTIFICATION

• **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.